Pain News and Research

Latest Pain News and Research

Iroko announces results from diclofenac Phase 3 study on post-surgical pain

Iroko Pharmaceuticals, LLC today announced Phase 3 study results that showed patients treated with the company's novel, submicron particle, lower-dose diclofenac (18mg and 35mg), a non-steroidal anti-inflammatory drug (NSAID), experienced significant pain relief post surgery compared with placebo>0.01 and P<0.001 respectively).

22 Jun 2012

Data from MAP Pharmaceuticals’ LEVADEX clinical studies to be presented at AHS meeting

MAP Pharmaceuticals, Inc. today announced that the Company will present data on LEVADEX (formerly MAP0004), an orally inhaled investigational drug for the acute treatment of migraine, at the 54th Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, CA, June 21-24, 2012.

22 Jun 2012

Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Teva Pharmaceutical Industries Ltd. announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax.

22 Jun 2012

Lead 8A analog can treat osteosarcoma in children

Jiayuh Lin, PhD, and colleagues at Nationwide Children's Hospital have developed a drug to target the most common cancerous bone tumor in children, osteosarcoma, using a version of the FDA-approved drug, Celebrex. The team will soon begin testing the drug using human and canine tumor cell lines thanks to a two-year, $200,000 grant from Alex's Lemonade Stand Foundation for Childhood Cancer.

22 Jun 2012

MCN Learning launches new Pain Scale app for Google Android users

MCN Learning, an internationally-recognized leader in healthcare education, announces the launch of the MCN Learning Pain Scale application for the Google Android mobile operating system.

22 Jun 2012

Pfizer receives FDA approval for Lyrica to manage neuropathic pain associated with SCI

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the use of Lyrica (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.

22 Jun 2012

Bowel disturbance common until the end

Patients treated by palliative care services experience bowel disturbances until the end of life, with severe problems increasing as death approaches, report Australian researchers.

21 Jun 2012

Levodopa/carbidopa intestinal gel reduces 'off' time in people with advanced PD

A new delivery method for levodopa/carbidopa, a common dual-drug Parkinson's disease (PD) regimen, significantly improved the duration of the drugs' effectiveness in people with advanced PD, according to research by Mount Sinai School of Medicine.

21 Jun 2012

Genetics play a significant role in determining side effects of opiates

Genetics play a significant role in determining which patients will suffer the most from the disturbing side effects of opiates, commonly prescribed painkillers for severe to moderate pain, according to a new Stanford University School of Medicine study, which pinpoints nausea, slowed breathing and potential for addiction as heritable traits.

21 Jun 2012

AHS scientific conference to focus on impact of traumatic brain injuries

The impact of traumatic injuries to the brain - whether sustained in combat or on the playing fields of America's schools - is a major topic for international migraine specialists the week of June 18 as they gather in Los Angeles for the 54th Annual Scientific Sessions of the American Headache Society. This is among many timely issues concerning headache, migraine, and brain injuries on the four-day agenda here which runs through Sunday morning, June 24.

21 Jun 2012

MountainView Hospital first in Nevada to use Xenex’s room disinfection device

In an ongoing effort to improve patient safety, MountainView Hospital today announced it is the first hospital in Nevada to use Xenex Healthcare Services' innovative germ-zapping room disinfection technology to keep patients even safer from infections.

21 Jun 2012

FDA approves CDC DENV-1-4 Real Time RT PCR Assay to treat dengue

The Centers for Disease Control and Prevention has developed a new diagnostic test to detect the presence of dengue virus in people with symptoms of dengue fever or dengue hemorrhagic fever. The test, called the CDC DENV-1-4 Real Time RT PCR Assay, has been authorized by the Food and Drug Administration for use in the United States and can be performed using equipment and supplies many public health laboratories already use to diagnose influenza.

21 Jun 2012

Sufficient cancer pain relief may mean frequent follow up

US study findings show that just over half of cancer patients receiving outpatient palliative care who have mild or moderate pain intensity at initial consultation, report an increase to moderate or severe pain intensity by first follow up.

20 Jun 2012

UMMS researcher receives Janssen Award for microRNA discovery

Longtime collaborators Victor R. Ambros, PhD, of the University of Massachusetts Medical School (UMMS) and Gary B. Ruvkun, PhD, of Massachusetts General Hospital and Harvard Medical School, were awarded the 2012 Dr. Paul Janssen Award for Biomedical Research today by Johnson & Johnson for their co-discovery of microRNA, tiny molecules that are now understood to play a powerful role in gene expression and regulation.

20 Jun 2012

Lobbying sinks efforts to impose restrictions on painkillers

Pharmacists and drugstores appear to have undone an effort to impose more strict controls on drug controls. Meanwhile, Accretive Health, the Chicago-based hospital-billing company which is under fire, is fighting back.

20 Jun 2012

Survey: 1 in 5 U.S. women experience sexual assault during their lifetime

Despite the fact that the majority of women presenting to emergency departments for care after sexual assault experience severe pain, very few receive pain treatment. These were the findings of a multi-site research study led by Samuel McLean, MD, MPH, director of the TRYUMPH Research Program in the Department of Anesthesiology at the University of North Carolina School of Medicine. The results were published online in the Journal of Pain on June 15, 2012.

20 Jun 2012

Christiana Care receives $10 million CMMI grant to design new model

Christiana Care Health System has been awarded a $10 million grant from the Center for Medicare and Medicaid Innovation to design a new care model that will harness pioneer information technology to transcend the gaps that currently exist within health care to provide more coordinated care and greater value for patients.

20 Jun 2012

AUA Foundation introduces It's Time to Talk About OAB campaign

On the heels of the fourth annual World Continence Week, the American Urological Association (AUA) Foundation has launched "It's Time to Talk About OAB," a nationwide education campaign designed to elevate awareness of Overactive Bladder (OAB), a common, yet often untreated condition, as a public health issue.

20 Jun 2012

Furiex initiates MuDelta Phase III studies in IBS-D

Furiex Pharmaceuticals, Inc. today announced dosing of the first patient in its Phase III randomized, double-blind, placebo-controlled studies evaluating efficacy, safety and tolerability of MuDelta (JNJ-27018966) in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

20 Jun 2012

Grunenthal to commercialize Horizon Pharma's DUEXIS in Latin America

Horizon Pharma, Inc. a biopharmaceutical company developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases, today announced that it entered into an exclusive agreement with Grunenthal for the commercialization of DUEXIS in Latin America.

19 Jun 2012